Keros Therapeutics (KROS) Competitors $14.32 0.00 (0.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$14.32 -0.01 (-0.03%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. AGIO, ARWR, IDYA, MESO, BEAM, HRMY, TWST, IRON, DNLI, and CNTAShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Agios Pharmaceuticals (AGIO), Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), Mesoblast (MESO), Beam Therapeutics (BEAM), Harmony Biosciences (HRMY), Twist Bioscience (TWST), Disc Medicine (IRON), Denali Therapeutics (DNLI), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Its Competitors Agios Pharmaceuticals Arrowhead Pharmaceuticals IDEAYA Biosciences Mesoblast Beam Therapeutics Harmony Biosciences Twist Bioscience Disc Medicine Denali Therapeutics Centessa Pharmaceuticals Agios Pharmaceuticals (NASDAQ:AGIO) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation. Do insiders & institutionals hold more shares of AGIO or KROS? 71.6% of Keros Therapeutics shares are owned by institutional investors. 4.3% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 20.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, AGIO or KROS? Agios Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Which has preferable earnings & valuation, AGIO or KROS? Agios Pharmaceuticals has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$37.04M54.73$673.72M$11.003.18Keros Therapeutics$3.55M163.85-$187.35M-$0.18-79.56 Does the media prefer AGIO or KROS? In the previous week, Agios Pharmaceuticals had 10 more articles in the media than Keros Therapeutics. MarketBeat recorded 13 mentions for Agios Pharmaceuticals and 3 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 1.11 beat Agios Pharmaceuticals' score of 0.22 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Keros Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AGIO or KROS more profitable? Agios Pharmaceuticals has a net margin of 1,590.42% compared to Keros Therapeutics' net margin of 1.96%. Keros Therapeutics' return on equity of 0.75% beat Agios Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals1,590.42% -3.39% -3.13% Keros Therapeutics 1.96%0.75%0.69% Do analysts rate AGIO or KROS? Agios Pharmaceuticals presently has a consensus price target of $56.33, suggesting a potential upside of 60.95%. Keros Therapeutics has a consensus price target of $30.56, suggesting a potential upside of 113.38%. Given Keros Therapeutics' higher probable upside, analysts plainly believe Keros Therapeutics is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryKeros Therapeutics beats Agios Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$581.61M$2.99B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-79.5617.7428.8623.83Price / Sales163.85178.75371.4866.02Price / CashN/A41.9535.4557.96Price / Book1.018.508.275.54Net Income-$187.35M-$55.06M$3.25B$259.28M7 Day Performance-0.97%-3.99%-3.73%-4.68%1 Month Performance6.79%9.58%4.29%4.36%1 Year Performance-70.86%6.70%25.87%17.89% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics2.5921 of 5 stars$14.32flat$30.56+113.4%-71.6%$581.61M$3.55M-79.56100News CoveragePositive NewsUpcoming EarningsAGIOAgios Pharmaceuticals4.0161 of 5 stars$39.36-3.0%$57.33+45.7%-21.3%$2.28B$37.04M3.50390News CoverageEarnings ReportARWRArrowhead Pharmaceuticals3.8355 of 5 stars$15.85-0.5%$43.71+175.9%-42.0%$2.19B$3.55M-11.32400News CoveragePositive NewsUpcoming EarningsGap UpIDYAIDEAYA Biosciences4.179 of 5 stars$24.97+5.6%$47.55+90.4%-42.8%$2.19B$7M-6.9580Upcoming EarningsMESOMesoblast0.775 of 5 stars$16.96+5.4%$18.00+6.1%+141.2%$2.17B$5.90M0.0080BEAMBeam Therapeutics2.6098 of 5 stars$21.12-4.7%$48.75+130.8%-37.9%$2.12B$63.52M-4.58510Upcoming EarningsInsider TradeGap DownHRMYHarmony Biosciences4.7824 of 5 stars$36.85-1.0%$51.00+38.4%+5.1%$2.12B$714.73M14.07200Positive NewsUpcoming EarningsTWSTTwist Bioscience3.5578 of 5 stars$35.25-2.2%$50.40+43.0%-36.5%$2.11B$312.97M-10.85990News CoverageUpcoming EarningsShort Interest ↑Gap DownIRONDisc Medicine3.5418 of 5 stars$60.78-0.3%$95.73+57.5%+36.3%$2.10BN/A-15.5130Positive NewsUpcoming EarningsInsider TradeDNLIDenali Therapeutics4.5811 of 5 stars$14.24-1.6%$33.71+136.8%-42.4%$2.07B$330.53M-5.33430News CoverageUpcoming EarningsCNTACentessa Pharmaceuticals3.2078 of 5 stars$15.42-1.0%$28.10+82.3%+63.4%$2.06B$6.85M-8.52200News CoverageAnalyst ForecastInsider Trade Related Companies and Tools Related Companies Agios Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives IDEAYA Biosciences Alternatives Mesoblast Alternatives Beam Therapeutics Alternatives Harmony Biosciences Alternatives Twist Bioscience Alternatives Disc Medicine Alternatives Denali Therapeutics Alternatives Centessa Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
